EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer

BACKGROUND: In early estrogen receptor (ER)-positive/HER2-negative breast cancer, the decision to administer chemotherapy is largely based on prognostic criteria. The combined molecular/clinical EndoPredict test (EPclin) has been validated to accurately assess prognosis in this population. In this s...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubsky, P., Filipits, M., Jakesz, R., Rudas, M., Singer, C. F., Greil, R., Dietze, O., Luisser, I., Klug, E., Sedivy, R., Bachner, M., Mayr, D., Schmidt, M., Gehrmann, M. C., Petry, C., Weber, K. E., Kronenwett, R., Brase, J. C., Gnant, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574544/
https://www.ncbi.nlm.nih.gov/pubmed/23035151
http://dx.doi.org/10.1093/annonc/mds334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574544/
https://www.ncbi.nlm.nih.gov/pubmed/23035151
http://dx.doi.org/10.1093/annonc/mds334

Ejemplares similares